Advances in Cancer ResearchGeorge F. Vande Woude, George Klein Elsevier, 29 juil. 2011 - 368 pages The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. A very special event the Nobel Minisymposium, “Molecular Oncology – From Bench to Bedside, held at the Karolinska Instituet, in Stockholm, Sweden, was marked the celebration of George and Eva Klein’s combined 160th birthday. To honor this occasion, this volume brings together contributions by their former students, colleagues and collaborators of the past fifty years into a volume of Advances in Cancer Research dedicated to George and Eva. Over a decade ago, a subdivision of ACR called “Foundations in Cancer Research was initiated and the tributes honoring the Kleins’ bodies of work presented at the minisymposium are especially appropriate for the series. |
Table des matières
| 1 | |
Immunotherapy by Allogeneic Stem Cell Transplantation | 25 |
Mnt Takes Control as Key Regulator of the MycMaxMxd Network | 61 |
Lytic Cycle Switches of Oncogenic Human Gammaherpesviruses | 81 |
No Life Without Death | 111 |
Control of Apoptosis in Human Multiple Myeloma by Insulinlike Growth Factor I IGFI | 139 |
cMYC Impairs Immunogenicity of Human B Cells | 167 |
Cancer Dormancy Lessons from a B Cell Lymphoma and Adenocarcinoma of the Prostate | 189 |
Therapeutic Targets of Multiple Angiogenic Factors for the Treatment of Cancer and Metastasis | 203 |
Novel ThreeDimensional Organotypic Liver Bioreactor to Directly Visualize Early Events in Metastatic Progression | 225 |
PDGF Receptors as Targets in Tumor Treatment | 247 |
Extracellular Matrix Nuclear and Chromatin Structure and Gene Expression in Normal Tissues and Malignant Tumors A Work in Progress | 275 |
Targeted Cancer Therapy Promise and Reality | 295 |
Restoration of WildType p53 Function in Human Tumors Strategies for Efficient Cancer Therapy | 321 |
| 339 | |
Autres éditions - Tout afficher
Advances in Cancer Research, Volume 97 George F. Vande Woude,George Klein Aucun aperçu disponible - 2007 |
Expressions et termes fréquents
Acad acute allogeneic angiogenesis angiogenesis inhibitors angiogenic antibodies antigen apoptosis ASCT binding Biol bioreactor Blood Bone Marrow Transplant breast cancer c‐myc cancer cells Cancer Res carcinoma caspase cell cycle cell death cell lines cellular chronic clinical core domain DNA‐binding donor drug effect epithelial Epstein‐Barr virus function gene expression graft‐versus‐host disease growth factor growth factor receptor GVHD human Hurlin IGF‐IR imatinib Immunol induce inhibition inhibitors interactions interferon Klein KSHV leukemia ligand liver lymphocytes lymphoma lytic cycle lytic cycle activation malignant mammary metastasis metastatic mice molecular molecules mouse multiple myeloma mutant p53 mutations Natl Nilsson nuclear Oncogene overexpression pathways patients PDGF receptor pericytes phosphorylation platelet‐derived growth factor Proc proliferation promoter prostate protein regulation relapse Ringden role signal transduction structure studies survival therapy tissue transcription factors translocation treatment tumor cells tumor suppressor tyrosine kinase VEGF viral vitro vivo wild‐type ZEBRA
Fréquemment cités
Page 335 - Participation of p53 protein in the cellular response to DNA damage.
Page 21 - MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures.
Page 334 - Eldeiry, WS, Tokino, T., Velculescu. VE, Levy, DB, Parsons. R., Trent, JM, Lin, D., Mercer, WE, Kinzler, KW, and Vogelstein, B.